£3.5M
Sartorius took a minority shareholding in the London startup through its corporate venture unit to support product commercialisation.
"The SPARTA platform will help customers optimize the design of nanoparticles at an early stage, even before the drug candidates move on to the clinic. We have teamed up to bring additional product commercialization and application expertise to the table to facilitate a swift transitioning from prototype to launch,"